Intellikine
Discovers and develops small molecule drugs that target signal transduction networks for the treatment of cancer, inflammation, and autoimmune disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
€282m (Public information from Dec 2011)
San Diego California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$12.5m | Seed | ||
$51.0m | Series B | ||
| N/A | $4.0m | Early VC | |
| N/A | $310m Valuation: $310m | Acquisition | |
| Total Funding | €61.4m | ||